Sex Differences in Long-Term Safety and Tolerability of GH Replacement Therapy in GH Deficient Adults
The Journal of Clinical Endocrinology & Metabolism · 2023
DOI: 10.1210/clinem/dgad013 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Tessa N A Slagboom und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Endocrinology, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Net…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Human Growth Hormone. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Context
Previous studies report that outcomes of growth hormone (GH) replacement therapy (GHRT) might be less beneficial in growth hormone deficient (GHD) women compared with men.
Objective
This study investigated possible contributing factors regarding this previously found sex difference.
Methods
This retrospective cohort study, conducted at a nationwide outpatient clinic (the Dutch National Registry of GH Treatment in Adults), included Dutch adult GHD men (n = 1335) and women (n = 1251) treated with GHRT. The patients’ baseline characteristics, details of GHRT, and the tolerability and long-term safety of GHRT were measured.
Results
During treatment, sensitivity analysis showed that insulin-like growth factor-1 (IGF-1) SD scores remained subnormal more often in women (P < 0.001), while scores above normal were more frequent in men (P < 0.001). Women reported more adverse events (P < 0.001), especially symptoms related to fluid retention, and more often needed a dose reduction or temporary stop of GHRT (P = 0.001). In percentages, both sexes equally discontinued GHRT, as was also true for the risk in developing type 2 diabetes mellitus, benign neoplasms, and tumor recurrence. The risk of developing malignant neoplasms was higher in men (P = 0.012).
Conclusion
Data obtained from the Dutch National Registry of GH Treatment in Adults indicate that GHD women might be treated suboptimally, reflected as lower IGF-1 status and lower GHRT tolerability, leading to more frequent changes in treatment regimen but not discontinuation of GHRT. Regarding long-term safety, we found a higher risk for development of malignancies in GHD men.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Section of Endocrinology, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
- Department of Internal Medicine, Division of Endocrinology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands.
ORCID-Profile: Tessa N A Slagboom, Christa C van Bunderen
Zitieren
APA
Slagboom, T. N. A., van Bunderen, C. C., van der Lely, A. J., & Drent, M. L. (2023). Sex Differences in Long-Term Safety and Tolerability of GH Replacement Therapy in GH Deficient Adults. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad013
Vancouver
Slagboom TNA, van Bunderen CC, van der Lely AJ, Drent ML. Sex Differences in Long-Term Safety and Tolerability of GH Replacement Therapy in GH Deficient Adults. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad013
BibTeX
@article{Slagboom2023,
author = {Slagboom, Tessa N A and van Bunderen, Christa C and van der Lely, Aart Jan and Drent, Madeleine L},
title = {Sex Differences in Long-Term Safety and Tolerability of GH Replacement Therapy in GH Deficient Adults},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
doi = {10.1210/clinem/dgad013}
}
EUVIMED